The status of neuroendocrine tumor imaging: From darkness to light?

Keyphrases

• Tumor 100%
• Molecular Imaging 100%
• Neuroendocrine Tumour Imaging 100%
• Positron Emission Tomography 50%
• Computed Tomography 50%
• Receptor Binding 50%
• Radiograph 50%
• Magnetic Resonance Imaging Techniques 50%
• Diffusion Magnetic Resonance Imaging (dMRI) 50%
• Anatomic 50%
• Precision Medicine 50%
• Functional Technique 50%
• Global Status 50%
• Diagnostic Imaging 50%
• Diagnostic Strategy 50%
• Functional Characterization 50%
• Neuroendocrine Tumor 50%
• Target Identification 50%
• Genomic Information 50%
• Magnetic Resonance Imaging Contrast Agents 50%
• Staged Treatment 50%
• Scintigraphy 50%
• Tumor Location 50%
• Treatment Selection 50%
• Parallel Analysis 50%
• Metabolic Targets 50%
• New Entity 50%
• Dynamic Contrast-enhanced 50%
• 111In-pentetreotide 50%
• Ultrasound Technique 50%
• Resonant Dynamics 50%
• Somatostatin Agonists 50%
• Biological Information 50%
• 18F-DOPA 50%
• Binding Peptide 50%
• Multidimensional Characterization 50%
• Multi-level Integration 50%
• 11C-5-HTP 50%
• 68Ga-DOTA-peptides 50%
• Metabolic Performance 50%

Medicine and Dentistry

• Neoplasm 100%
• Molecular Imaging 100%
• Tumor Imaging 100%
• Neuroendocrine Tumor 100%
• Positron Emission Tomography 50%
• Magnetic Resonance Imaging 50%
• Morphology 50%
• Personalized Medicine 50%
• Computer Assisted Tomography 50%
• Sensitivity and Specificity 50%
• Diagnostic Imaging 50%
• Imaging Technique 50%
• Specific Tumor 50%
• Indium 111 50%
• Diffusion MRI 50%
• Fluorine-18 50%
• Scintigraphy 50%
• Ultrasonography 50%
• Carbon 11 50%
• Tetraxetan 50%
• Somatostatin 50%
• Receptor Binding 50%
• Gallium 68 50%
• DOPA 50%
• Target Identification 50%
• Pentetreotide 50%